
SciSparc Ltd. (NASDAQ:SPRC) traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures Inc. (TSXV:MIZA), a publicly traded firm on Canada's TSX Venture Exchange
The Tel Aviv-based pharmaceutical company develops treatments for central nervous system and rare disorders. It finalized its deal with Miza III on Oct. 9